CMS Tells Mylan It Incorrectly Classified EpiPen To Pay Lower Medicaid Rebates, Lawmakers Upset

CMS has informed Mylan it incorrectly classified EpiPen as a generic under the Medicaid rebate program, which caused financial consequences for federal and state governments by reducing the amount of quarterly rebates Mylan owed for its product, an agency official told Inside Health Policy Friday (Sept. 2). The agency faces growing pressure from key lawmakers to explain EpiPen's rebate classification, which the agency told Dey Laboratories (now Mylan Specialty) back in a 1997 letter was “fitting and proper,” and...